Better outcomes, less medication.
Our clinical study shows you don’t need high GLP-1 doses to achieve lasting weight loss.
Why we ran the TRIM study
Can lower doses of GLP-1 still deliver results? We tracked 2,700+ members over a year to find out, pairing low-dose GLP-1 medication with behavioral support in a real-world setting.
Real-world outcomes from
2,700+ participants
16.7% avg. weight loss at 12 months
Real-world data from members in our clinical weight loss program.
55% lower
GLP-1 use
Members reached outcomes using just a third of the standard cumulative dose.
85% lost >10% of their body weight
Members achieved these outcomes using significantly less medication than traditional protocols.
78% come off meds successfully
We tracked outcomes for a full year, so we know the results are durable.
What makes Embla work
Embla isn’t a medication program. It’s behavior-first care, clinically designed to reduce reliance on GLP-1s from day one.
Clinical oversight
Our clinicians and nurses track every member, ensuring a safe and individualized treatment.
1:1 health coaching
1:1 health coaching from specialists in behavior, nutrition and physical activity.
Personal care
Personalized care plans built around each member’s needs.
Built-in tapering
Gradual tapering to help members come off medication successfully.
Why it matters for employers
Big results. Small
pharmacy footprint.
We achieved comparable — or better — weight loss results using just 45% of the typical GLP-1 dose. That’s fewer claims and lower total cost of care.
Outcomes that
last beyond the script
Members who successfully tapered off medication maintained weight loss for at least 6 months — with no significant rebound effect.
Behavior-first
means cost control
Coaching drives the difference. By focusing on daily habits, not just prescriptions, we lower both short-term spend and long-term risk.
Why it matters for your population
Even modest weight loss drives measurable health improvements:
42% lower risk of type 2 diabetes (at 13% weight loss)
Up to 50% reduction in sleep apnea symptoms (with 10–15% weight loss)
Improved mobility, energy, and quality of life
Ready to take control of GLP-1 spend?
Let’s talk about how Embla can reduce costs and improve health outcomes across your employee population.